Back to Search Start Over

Implementation of a standardised and quality-assured enhanced gonococcal antimicrobial surveillance programme in accordance with WHO protocols in Kampala, Uganda

Authors :
Kakooza, Francis
Musinguzi, Patrick
Workneh, Meklit
Walwema, Richard
Kyambadde, Peter
Mande, Emmanuel
Lubega, Christopher
Nakasi, Jhamira M.
Kiggundu, Reuben
Hamill, Matthew M.
Bagaya, Bernard S.
Lamorde, Mohammed
Unemo, Magnus
Manabe, Yukari C.
Kakooza, Francis
Musinguzi, Patrick
Workneh, Meklit
Walwema, Richard
Kyambadde, Peter
Mande, Emmanuel
Lubega, Christopher
Nakasi, Jhamira M.
Kiggundu, Reuben
Hamill, Matthew M.
Bagaya, Bernard S.
Lamorde, Mohammed
Unemo, Magnus
Manabe, Yukari C.
Publication Year :
2021

Abstract

Objectives: The emergence of multidrug-resistant Neisseria gonorrhoeae (NG) is a major global health threat necessitating response and control measures. NG antimicrobial resistance (AMR) surveillance data from sub-Saharan countries is exceedingly limited. This paper aims to describe the establishment, design and implementation of a standardised and quality-assured gonococcal surveillance programme and to describe the susceptibility patterns of the cultured gonococcal isolates in Kampala, Uganda. Methods: From March 2018 to September 2019, using the WHO Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP) protocol, consecutive males with urethral discharge syndrome were recruited from 10 surveillance sites in Kampala City, Uganda, in collaboration with the Ministry of Health. Males completed a questionnaire and provided a urethral swab specimen. Culture, identification and antimicrobial susceptibility testing (Etest) were performed. Results: Of the 1013 males recruited, 73.1% (740/1013) had a positive Gram stain and 51.1% (n=518) were culture-positive for NG. Using Etest (458 isolates), the resistance to ciprofloxacin was 99.6%. Most isolates were susceptible to azithromycin, cefoxitin and gentamicin, that is, 99.8%, 98.5% and 92.4%, respectively, and all isolates were susceptible to ceftriaxone and cefixime. Conclusions: We established a standardised, quality-assured WHO EGASP. Using Etest, 458 isolates were characterised, with associated epidemiological surveillance data, in 1.5 years, which by far exceed the minimum 100 isolates per year and country requested in the WHO Global GASP, to detect AMR levels with confidence. These isolates with the epidemiological data can be used to develop population level interventions.<br />Funding Agency:United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA 1U2GGH001744-01

Details

Database :
OAIster
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1234119917
Document Type :
Electronic Resource
Full Text :
https://doi.org/10.1136.sextrans-2020-054581